Children’s Triaminic and Theraflu Recalled for Poisoning Risk

When you give your child medicines, you want those antibiotics to make your young one feel better, not worse. According to the United States Consumer Product Safety Commission, a recent manufacturing error has caused bottles of Triaminic and Theraflu to fail the child resistant closure requirements. This means that the bottles were not sealed safely. Because of this, children may be able to pry the lid off of the medicine and drink it. All medicines are supposed to have child-proof locks on the caps so that children cannot pull the cap off and drink the medicine out of curiosity or hunger.
If they overdose on the medicines, they can poison themselves. Triaminic wants to recollect all bottles of medicine that are not child-proofed and will repair the bottles or administer a refund to anyone who has purchased the product. About 2.3 million units have been affected by the recall. The main concern with these medicines is the fact that they contain traces of acetaminophen and diphenhydramine. Both of these medications can be dangerous and even fatal in strong doses.
There are a variety of different Triaminic and Theraflu products that are involved in the recall. All are syrups. The recall includes but is not limited to Theraflu Warming liquid, Triaminic Daytime Cold and Cough, Triaminic Fever Reducer, Triaminic Long Acting Cough, and Triaminic Nighttime Cold and Cough. If your child consumes a dangerous amount of any one of these medications, then you have the right to seek compensation from the company. This is because they had a responsibility to create a safe and reliable product and were not able to accomplish this goal.

Have You Been Injured By A Defective Product?

If you or a loved one has been injured due to a faulty product you need to speak with an experienced defective product attorney as soon as possible. Please contact us online or call our office directly at 855.GA.INJURY or 404.991.5950 to schedule your free consultation.

By
Published on:
Updated:

Comments are closed.

Contact Information